Dan Rader's guest appearances

Dan Rader

SuccessVets: Advice For Veterans On Life After The Military

DC Tech Stories

The Peter Attia Drive

Tom Morkes

Justin Sloan

John Davison

Elizabeth Lindsey

Kate Rabinowitz

Doug McCormick

Clay Clark

Tom Wolfe

Lee Cockerell

Matt Butler

Larry Broughton

Dan Evans

Anthony Garcia

Brian Jacobs

Michael Betancourt

OwlTail

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter’s Weekly Newsletter Dan Rader is a Professor at the Perelman School of Medicine at the University of Pennsylvania, where he conducts translational research on lipoprotein metabolism and atherosclerosis with a particular focus on the function of high-density lipoproteins (HDLs). In this episode, Dan goes in-depth on HDL biology, including the genesis of HDL, its metabolism, function, and how this relates to atherosclerotic cardiovascular disease (ASCVD). He explains why having high HDL-C levels does not directly translate to a low risk of cardiovascular disease and reveals research pointing to a better way to measure the functionality of HDL and predict disease risk. He also goes into detail on the role of HDL in reverse cholesterol transport and the benefits this has for reducing ASCVD. Additionally, Dan discusses the latest thinking around the association between HDL cholesterol and neurodegenerative diseases and ends the conversation with a discussion of how the latest research on HDL provides a promising outlook for ongoing trials and future therapeutic interventions. We discuss:  The lipidology of apoB and apoA [4:00]; A primer on the high-density lipoprotein (HDL): genesis, structure, and more [9:30]; How the lipoprotein system differs in humans compared to other mammals [20:00]; Clarifying the terminology around HDL and apoA [25:30]; HDL metabolism [31:45]; CETP inhibitors for raising HDL-C: does it reduce CVD risk? [34:45]; Why it’s so important to have hard outcome trials in the field of cardiovascular medicine [42:30]; SR-B1: an HDL receptor important for cholesterol efflux [48:00]; The association between HDL levels and atherosclerosis: are they causally linked? [53:15]; How insulin resistance is impacting HDL, and how HDL-C provides insights into triglyceride metabolism [58:00]; Disappointing results from the studies of niacin—a drug that raises HDL-C and lowers apoB [1:08:15]; HDL lipidation, dilapidation, and reverse cholesterol transport [1:12:00]; Measuring the cholesterol efflux capacity of HDL: a better predictor of ASCVD risk than HDL-C? [1:22:00]; A promising new intervention that may promote cholesterol efflux and reverse cholesterol transport [1:32:45]; The association between HDL cholesterol and neurodegenerative diseases [1:34:00]; Challenges ahead, a promising outlook, and the next frontier in lipidology [1:44:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

<a href="https://peterattiamd.com/danrader/?utm_source=podcast-feed&amp;utm_medium=referral&amp;utm_campaign=230130-pod-danrader&amp;utm_content=230130-pod-danrader-podfeed" rel="nofollow" target="_blank"> View the Show Notes Page for This Episode</a> <a href="https://peterattiamd.com/subscribe/?utm_source=podcast-feed&amp;utm_medium=referral&amp;utm_campaign=230130-pod-danrader&amp;utm_content=230130-pod-danrader-podfeed" rel="nofollow" target="_blank"> Become a Member to Receive Exclusive Content</a> <a href="https://peterattiamd.com/newsletter/?utm_source=podcast-feed&amp;utm_medium=referral&amp;utm_campaign=230130-pod-danrader&amp;utm_content=230130-pod-danrader-podfeed" rel="nofollow" target="_blank"> Sign Up to Receive Peter’s Weekly Newsletter</a> Dan Rader is a Professor at the Perelman School of Medicine at the University of Pennsylvania, where he conducts translational research on lipoprotein metabolism and atherosclerosis with a particular focus on the function of high-density lipoproteins (HDLs). In this episode, Dan goes in-depth on HDL biology, including the genesis of HDL, its metabolism, function, and how this relates to atherosclerotic cardiovascular disease (ASCVD). He explains why having high HDL-C levels does not directly translate to a low risk of cardiovascular disease and reveals research pointing to a better way to measure the functionality of HDL and predict disease risk. He also goes into detail on the role of HDL in reverse cholesterol transport and the benefits this has for reducing ASCVD. Additionally, Dan discusses the latest thinking around the association between HDL cholesterol and neurodegenerative diseases and ends the conversation with a discussion of how the latest research on HDL provides a promising outlook for ongoing trials and future therapeutic interventions. We discuss: <ul> <li>The lipidology of apoB and apoA [4:00];</li> <li>A primer on the high-density lipoprotein (HDL): genesis, structure, and more [9:30];</li> <li>How the lipoprotein system differs in humans compared to other mammals [20:00];</li> <li>Clarifying the terminology around HDL and apoA [25:30];</li> <li>HDL metabolism [31:45];</li> <li>CETP inhibitors for raising HDL-C: does it reduce CVD risk? [34:45];</li> <li>Why it’s so important to have hard outcome trials in the field of cardiovascular medicine [42:30];</li> <li>SR-B1: an HDL receptor important for cholesterol efflux [48:00];</li> <li>The association between HDL levels and atherosclerosis: are they causally linked? [53:15];</li> <li>How insulin resistance is impacting HDL, and how HDL-C provides insights into triglyceride metabolism [58:00];</li> <li>Disappointing results from the studies of niacin—a drug that raises HDL-C and lowers apoB [1:08:15];</li> <li>HDL lipidation, dilapidation, and reverse cholesterol transport [1:12:00];</li> <li>Measuring the cholesterol efflux capacity of HDL: a better predictor of ASCVD risk than HDL-C? [1:22:00];</li> <li>A promising new intervention that may promote cholesterol efflux and reverse cholesterol transport [1:32:45];</li> <li>The association between HDL cholesterol and neurodegenerative diseases [1:34:00];</li> <li>Challenges ahead, a promising outlook, and the next frontier in lipidology [1:44:45]; and</li> <li>More.</li> </ul> Connect With Peter on <a href="https://twitter.com/PeterAttiaMD" rel="nofollow" target="_blank">Twitter</a>, <a href="https://www.instagram.com/peterattiamd/" rel="nofollow" target="_blank">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/" rel="nofollow" target="_blank">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg" rel="nofollow" target="_blank">YouTube</a>

#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.

Elizabeth Barth

Jabali Williams

Mariesa Dale

According to InVision’s Comprehensive Guide to Design Systems, “A design system is a collection of reusable components, guided by clear standards, that can be assembled together to build any number of applications.”So what does that mean for us techies? How doe tech companies create, utilize, and enforce these systems? Frankly I had no idea - so I brought in the experts!Elizabeth Barth: Creative Director, ThreeSpotDan Rader: Interactive Art Director ISLJabali Williams: Director of User Experience at CHIEFMariesa Dale: Manager, Product Design Pivotal Labs DCThey walked me through how they think of design systems, some pros and cons, and how their companies put them into practice.

According to InVision’s Comprehensive Guide to Design Systems, “A design system is a collection of reusable components, guided by clear standards, that can be assembled together to build any number of applications.” So what does that mean for us techies? How doe tech companies create, utilize, and enforce these systems? Frankly I had no idea - so I brought in the experts! Elizabeth Barth: Creative Director, ThreeSpot Dan Rader: Interactive Art Director ISL Jabali Williams: Director of User Experience at CHIEF Mariesa Dale: Manager, Product Design Pivotal Labs DC They walked me through how they think of design systems, some pros and cons, and how their companies put them into practice.

Elizabeth Barth, Dan Rader, Jabali Williams, Mariesa Dale: Design Systems

Is one of your priorities to land a job near your ideal location? Are you having trouble dealing with your command as you transition from the military? These are just a couple of the things that Dan Rader talks about in this interview. Dan was a Navy nuclear surface warfare officer who led sailors in the operation and maintenance of aircraft carrier power plants. Today, he is a Reliability Engineering Supervisor at OGE Energy Corporation, an electric utility company that services over 800000 customers in Oklahoma and Arkansas. And by the way, his company is hiring and Dan would love to talk to you if you're interested in a career in the energy industry!

Is one of your priorities to land a job near your ideal location? Are you having trouble dealing with your command as you transition from the military? These are just a couple of the things that Dan Rader talks about in this interview. Dan was a Navy nuclear surface warfare officer who led sailors in the operation and maintenance of aircraft carrier power plants. Today, he is a Reliability Engineering Supervisor at OGE Energy Corporation, an electric utility company that services over 800000 customers in Oklahoma and Arkansas. And by the way, his company is hiring and Dan would love to talk to you if you're interested in a career in the energy industry!

Interview with Dan Rader